The European peptide therapeutics market is anticipated to project a CAGR of 4.3%, during the forecast period. Europe is estimated to have a significant share in the global peptide therapeutics market. The major factors that drive the growth of the market include the rising prevalence of cancer, geriatric population coupled with the increased investments in the healthcare sector across the major economies of the region. 

The European peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into parenteral administration and oral administration. On the basis of application, the market is segmented into cancer, metabolic disorder (diabetes & obesity), gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others including chronic kidney diseases, osteoporosis, and autoimmune disorder. Among these applications, metabolic disorder dominates the market in Europe. The increasing prevalence of diabetes globally created demand for insulin and hence drives the market growth.

Visit for Global Peptide Therapeutics Market Report at: https://www.omrglobal.com/industry-reports/peptide-therapeutics-market

Geographically, the European peptide therapeutics market is segmented into the UK, Germany, France, Italy, Spain, Rest of Europe. Germany accounted for a major share in the market in 2019. Rising chronic diseases and metabolic disorders in the country have given rise to the increased adoption of peptides for the treatment of these diseases. Other factors including the presence of key players, rise in per capita healthcare expenditure, and rise in research related to the development of synthetic peptides have contributed significantly to the growth of the market in the country.

Furthermore, some of the key players in the market include Novo Nordisk A/S, Eli Lilly & Co., AstraZeneca Plc, CordenPharma International GmbH, Bachem Holding AG, and Sanofi SA. These companies are using several strategies to expand market share and gain a competitive advantage over their competitors. The strategies include new product launches, mergers and acquisitions, partnerships, and collaborations. For instance, in July 2020, Germany-based CordenPharma had expanded peptide manufacturing capacity in CordenPharma Colorado, its GMP API facility in Boulder, CO (US). The company announced this expansion of its solid-phase peptide manufacturing capacity to fulfill the growing demand for peptide APIs.

Research Methodology

The market study of the European peptide therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market.
• Authentic public databases 
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for drug manufacturing companies, pharmaceutical companies, insulin manufacturers, diabetes management companies, government organizations, regulatory bodies, hospitals & pharmacies, research institutes, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models. 

Market Segmentation:

1. European Peptide Therapeutics Market Research and Analysis by Route of Administration
2. European Peptide Therapeutics Market Research and Analysis by Application

The Report Covers:

• Comprehensive research methodology of the European peptide therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European peptide therapeutics market.
• Insights about market determinants which are stimulating the European peptide therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.